Comprehensive review highlights `Acinetobacter baumannii` resistance mechanisms, emerging therapies including antimicrobial peptides, and vaccine development challenges
Background
Acinetobacter baumannii is a critically important Gram-negative pathogen, globally recognized for its significant contribution to healthcare-associated infections (HAIs), particularly within intensive care units (ICUs). Its remarkable adaptability allows it to persist tenaciously in hospital environments, form robust biofilms on medical devices, and skillfully evade host immune responses. These capabilities have fueled the rapid and alarming emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, rendering many last-resort antibiotics ineffective. The resulting high morbidity, mortality, and substantial economic burden underscore an urgent and unmet clinical need for novel, effective therapeutic strategies beyond the failing conventional antimicrobial arsenal. This review addresses the critical gap in understanding and combating this formidable pathogen.
Study Design
This narrative review was meticulously conducted through a comprehensive literature search across major scientific databases, including PubMed, Scopus, Web of Science, and Google Scholar. The authors focused on synthesizing research primarily published over the past two decades to capture the most relevant and recent advancements. The review's scope encompassed a detailed analysis of Acinetobacter baumannii's global epidemiology, identification of vulnerable patient populations, and an in-depth exploration of its diverse mechanisms of antimicrobial resistance. Furthermore, it critically assessed the clinical and economic impacts of these infections, alongside a thorough evaluation of both current and emerging therapeutic strategies, specifically highlighting antimicrobial peptides, bacteriophage therapy, and the progress in vaccine development.
Results
The review comprehensively summarizes Acinetobacter baumannii's alarming global epidemiology, emphasizing its prevalence in healthcare-associated infections and the rapid rise of MDR and XDR strains. It elucidates the pathogen's sophisticated mechanisms of antimicrobial resistance, including its ability to produce various β-lactamases, modify drug targets, and efflux pumps, alongside its capacity to form resilient biofilms that shield it from antibiotics and host immunity. These factors contribute significantly to its persistence in hospital settings and its formidable ability to evade host immune responses. > The review highlights that while conventional antibiotics are increasingly failing, alternative treatments such as antimicrobial peptides, bacteriophage therapy, and several vaccine candidates demonstrate promising preclinical efficacy, offering critical new avenues for intervention. However, a key finding is the identification of significant limitations underlying current and emerging strategies, primarily the pathogen's rapid evolution of resistance, its sophisticated immune evasion tactics, and considerable antigenic variability, which complicate vaccine design and long-term therapeutic effectiveness.
Why It Matters
This comprehensive review critically informs researchers, clinicians, and biohackers about the escalating threat posed by Acinetobacter baumannii, particularly its MDR and XDR forms. The insights into its resistance mechanisms and the limitations of current therapies are vital for guiding the development of next-generation antimicrobial strategies. For those exploring novel interventions, the discussion on antimicrobial peptides and bacteriophage therapy provides a strong rationale for their continued investigation as potent alternatives to conventional antibiotics. The emphasis on systems biology and multitarget approaches suggests that future protocols may involve synergistic combinations of agents or innovative vaccine platforms designed to overcome the pathogen's adaptability. This work underscores that a paradigm shift is needed in combating Acinetobacter baumannii, moving towards integrated, adaptive strategies to improve patient outcomes in severe healthcare-associated infections.